Flexible Dosing of Oral Treatments in mCRC

COR2ED Medical Education: In this podcast, Sven De Keersmaecker, RN and Assoc. Prof. Gerald Prager, MD discuss flexible dosing regimens of the oral treatments regorafenib, trifluridine / tipiracil (TAS-102) and capecitabine to optimise treatment duration and to manage adverse events in patients with metastatic colorectal cancer.  The two experts also discuss the importance of keeping patients on treatment to optimise outcomes whilst managing side effects and ensuring the best possible quality of life. Treatment strategies are discussed as well as key data from the ReDOS and REARRANGE trials. The experts also discuss the importance of the nurse and other multi-disciplinary team members in terms of adverse event management and treatment adherence. Sven De Keersmaecker RN is Study Co-ordinator at Antwerp University Hospital in Belgium and Dr Gerald Prager is a Medical Oncologist and Associate Professor at Medical University of Vienna in Austria

There are no comments yet.

Please log in to write the first comment.